Once-daily administration of phosphodiesterase type 5 inhibitors has been shown to correct erectile dysfunction (ED).
To evaluate the long-term efficacy and safety after once-daily oral administration of udenafil 75 mg in men with ED.
Udenafil, a cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor, has been developed to treat erectile dysfunction. We evaluated the effect of age on the pharmacokinetics and tolerability of udenafil.
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
